Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan
You may also be interested in...
Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center in Asia
Deal to build integrated Bangalore facility cements ten-year partnership between the U.S. pharma and the Indian contract research organization.
Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center in Asia
Deal to build integrated Bangalore facility cements ten-year partnership between the U.S. pharma and the Indian contract research organization.
After 10-year Partnership, Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center In Asia
MUMBAI - Bristol-Myers Squibb and Syngene - Biocon's contract research services arm - cemented a 10-year long association with the opening of what is called Asia's largest research facility near Bangalore. Syngene was established in 1994 and was the first to offer contract research services out of India. Syngene has now grown to become Biocon's fastest growing arm and has research alliances with Novartis and Merck